Table 3 Long-term post-operative outcomes
Outcome | Pre-op levosimendan (n = 40) | No-levosimendan (n = 22) | Total (n = 62) | P-value |
|---|---|---|---|---|
NYHA class at 3 months | 0.73 | |||
1–2 | 32 (82.1) | 16 (76.2) | 48 (77.4) | |
3–4 | 7 (17.9) | 5 (23.8) | 12 (19.4) | |
Laboratory at 3 months | ||||
Creatinine—mg/dL | 0.9 (0.75–1.17) | 0.94 (0.83–1.1) | 0.93 (0.8–1.13) | 0.54 |
Bilirubin—mg/dL | 0.61 (0.44–0.9) | 0.61 (0.5–0.74) | 0.59 (0.49–0.72) | 0.47 |
Albumin—g/dL | 3 (2.8–3.2) | 3.4 (3.3–3.7) | 3.9 (3.4–4.1) | 0.02 |
Right heart catheterization | ||||
CO—l/min | 4 (3.5–4.4) | 4.4 (4.2–5.3) | 4 (3.6–4.5) | 0.02 |
PCWP—mmHg | 11 (8–17) | 9 (5–14) | 11 (8–15) | 0.15 |
mPA—mmHg | 23 (18–27) | 19 (14–24) | 21 (18–27) | 0.21 |
mRA—mmHg | 11 (8–14) | 5 (3–9) | 10 (6–13) | 0.004 |
PVR—wood units | 2.2 (1.7–3) | 1.8 (1.7–1.9) | 1.9 (1.7–2.7) | 0.52 |
Readmissions | ||||
14 days | 6 (15.4) | 3 (14.3) | 9 (14.5) | > 0.99 |
3 months | 7 (17.9) | 5 (23.8) | 12 (19.4) | 0.73 |
1 year | 27 (69.2) | 13 (61.9) | 40 (64.5) | 0.56 |
Long-term complications—Any | 20 (50) | 9 (40.9) | 29 (46.8) | 0.46 |
Long term mortality—no | ||||
60 days | 1 (2.5%) | 1 (4.5%) | 2 (3.2) | > 0.99 |
90 days | 1 (2.5%) | 1 (4.5%) | 2 (3.2) | > 0.99 |
Total | 4 (10) | 6 (27.3) | 10 (16.1) | 0.64 |